Grant funding is not free money. It has rights attached.

If public money paid for any part of your research and development, there are three things in your intellectual property position that no contract can undo. Most founders find out during due diligence.

Two founders develop a rapid test strip that detects a common livestock disease in under fifteen minutes, at a fraction of the cost of a laboratory panel. The science comes out of a partnership with a university veterinary faculty. A national research grant covers R1 200 000 of the development work. Three years of validation follow.

Then a European animal health company offers an exclusive licence and wants to manufacture and distribute from Rotterdam. The term sheet is agreed. The warranties schedule arrives. And someone finally asks the question nobody asked at the start: who owns this, and what is attached to it?

The answer is not in the shareholders' agreement. It is in a statute neither founder has read.

The Act is broader than founders assume

The Intellectual Property Rights from Publicly Financed Research and Development Act 51 of 2008 has a reputation as a universities-and-science-councils statute. That reputation is wrong, and expensively so.

The Act reaches intellectual property emanating from publicly financed research and development, which means research and development undertaken using funds allocated by a funding agency. Scholarships and bursaries are carved out. Very little else is. The category of people the Act binds is not limited to higher education institutions and science councils.

So the question is not "am I a university". The question is: where did the money come from.

Founders routinely fail to recognise public money as public money when it arrives through an intermediary, a corporate programme, a partnership with an institution, or a departmental innovation fund. The character of the money is fixed by its source, not by the envelope it arrived in. Trace it back.

Three things you cannot draft around

1. The state holds a licence in your intellectual property.

Every intellectual property transaction over intellectual property caught by the Act must give the state an irrevocable, royalty-free licence to use that intellectual property, or have it used, anywhere in the world, for the health, security and emergency needs of the Republic. That sits in section 11.

This is not a term you negotiate. If your agreement is silent on it, the obligation does not vanish. Your agreement is simply non-compliant, and you have given a warranty you cannot support.

2. If you sit on it, the state can require you to license it.

Section 14 gives the state walk-in rights. The National Intellectual Property Management Office (NIPMO) reviews non-commercialised intellectual property, consults with the recipient, and where those consultations do not produce commercialisation, may require the recipient to grant a licence in any field of use to any person on reasonable terms.

Exclusivity in publicly funded work is conditional. It is held on the basis that you will do something with it.

3. The people who made it have a statutory share.

Section 10 sets a floor for benefit sharing with intellectual property creators: at least 20% of the first R1 million of gross revenue from the intellectual property, and at least 30% of net revenue after that.

Note what this is. It is the legislature saying that contribution to the creation of value carries an entitlement, and that the entitlement cannot be drafted below a floor. Most founders in this position have never told their researchers this.

There is a fourth item that behaves the same way. Assignments and offshore transactions need NIPMO approval. For an offshore assignment, the case that has to be made includes showing that there is insufficient capacity in the Republic to commercialise the intellectual property locally. Approval is a precondition, not a formality you attend to afterwards.

For our two founders and their Rotterdam buyer, that single point is the difference between a deal that closes and a deal that sits.

The one exit, and why it closes early

Research and development funded at full cost by a private entity falls outside the Act.

That is a real and useful exit. It is also the one founders miss, because of timing. Full costing has to be established at the start of the project, before the intellectual property exists. You cannot pay the full cost retrospectively and lift already-created intellectual property out of the Act's reach.

The decision point is at contracting. By the time the test strip works, the moment has passed.

The strongest objection, and the answer

The honest counterargument runs like this: walk-in rights have never been meaningfully exercised in South Africa, and the American march-in equivalent that inspired them has never been used either. Why should a founder care about a right that sits unused?

Because enforcement is not the risk. Diligence is.

An investor's intellectual property warranty asks you to confirm that the company owns or has the right to use its intellectual property, free of encumbrance. A statutory licence held by the state is an encumbrance. An unapproved offshore transaction is a defect. Neither has to be exercised or challenged to do damage. They only have to be found.

What they do is reprice the deal, extend the closing, or move the risk into an indemnity that a founder carries personally long after the money lands. That is the outcome, and it happens in the data room, not in a courtroom.

What to do this week

• Trace every rand that funded your research and development back to its original source. Intermediaries do not change what the money is.

• Pull the funding agreement and find the intellectual property clause. Read it against the Act, not instead of it. Where they conflict, the Act wins.

• On any new project involving a private funder, fix the full-cost position in writing at the start.

• Name your intellectual property creators and record their benefit-sharing entitlement now, while the relationship is good.

• Get NIPMO approval before any offshore transaction or assignment.

• Disclose the position in diligence. An unfavourable position that is disclosed is survivable. An undisclosed one is a warranty breach.

  
  

The pattern

This series keeps returning to one failure: you can create the value and still not own it.

Publicly funded work adds a sharper version. You can own it outright, hold the registrations, sit on the balance sheet as proprietor, and still not control what happens to it. Ownership and control came apart the day the grant was paid, and nobody said so out loud.

Say it out loud at the start, and it is a term. Discover it at exit, and it is a discount.

Get the Collaboration Agreement, built for research, development and joint-build arrangements under South African law. R595 in the TSL shop.

Publicly funded intellectual property is one of the few areas where a template is the starting point and not the finish. Where a funding agency, science council or university sits on the other side of your agreement, the drafting has to be specific to that deal.

Legal information, current as at 1 August 2026. Not legal advice.